The EUnetHTA JA 2 activities addressed all relevant phases of the Life Cycle of health technology development including the pre-licensing phase (in early scientific advice (Early Dialogues) and market entry through the early assessments of the evidence in rapid REAs and additional data and evidence collection
The European Medicines Agency (EMA) and the European network for Health Technology Assessment (EUnetHTA) published today a report on their implementation of the joint work plan covering the period between November 2012 and December 2015.
EUnetHTA JA3 is poised to start its activities June 1, 2016. Zorginstituut Nederland,the EUnetHTA JA3 Coordinator, is currently recruiting to fill a number of EUnetHTA JA3 positions – application deadline is April 18.
Following a successful contribution to the methodological guidance development in EUnetHTA JA (2010-2012), EUnetHTA continued its efforts in JA2 as well.
We are pleased to announce that as of today, 11March 2016, the draft methodological reflection paper “Personalised medicine and co-dependent technologies, with a special focus on study design issues”, produced within WP7 - Subgroup 3, has entered the public consultation phase. This consultation will take place between 11 March and 15 April 2016.